<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471376</url>
  </required_header>
  <id_info>
    <org_study_id>WJP20200708</org_study_id>
    <nct_id>NCT04471376</nct_id>
  </id_info>
  <brief_title>The Effect of Sugammadex During Motor Evoked Potentials Monitoring in Neurosurgical Patients</brief_title>
  <official_title>The Effect of Sugammadex During Motor Evoked Potentials Monitoring in Neurosurgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial motor evoked potential (TcMEP) monitoring is conventionally performed during
      neurosurgical procedures without or with minimal neuromuscular blockade (NMB) because of its
      potential interference with signal interpretation. However, full blockade offers increased
      anesthetic management options and facilitates surgery. Here, investigators want to assess the
      effect of Sugammadex during TcMEP in adult patients. Sugammadex is designed to encapsulate
      rocuronium and reverse rocuronium-induced neuromuscular blockade. 138 neurosurgical or
      orthopedic surgical patients undergoing thoracic or lumbar spinal cord surgery will be
      randomly divided into 2 groups: Sugammadex and control group. Sugammadex group received
      rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2
      mg/kg of Sugammadex will be infused when conducting TcMEP. No muscle relaxant will be used in
      control group. The primary outcome is the latency and amplitude of TcMEP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The latency and amplitude of MEP</measure>
    <time_frame>5 minutes after cutting dura mater</time_frame>
    <description>The numbers of latency and amplitude from MEP monitoring</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Sugammadex</condition>
  <arm_group>
    <arm_group_label>Sugammadex group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Sugammadex and control group. Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP</description>
    <arm_group_label>Sugammadex group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years

          -  ASA status I-II

          -  Neurosurgical or orthopedic surgical patients undergoing thoracic or lumbar spinal
             cord surgery

          -  tcMEP monitoring during the surgery

          -  Informed consent signed by patients

        Exclusion Criteria:

          -  BMI ≥35

          -  Epilepsy or use of antiepileptic drugs

          -  MEP stimulate or record site infection

          -  Anemia, hemoglobin &lt;110g/L

          -  Women who are pregnant or breastfeeding

          -  Inhalation anesthesia during the surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tian Tan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <phone>8610-59976660</phone>
      <email>ruquan.han@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 19, 2020</last_update_submitted>
  <last_update_submitted_qc>July 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Yuming Peng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

